Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar

Madrigal Pharmaceuticals (MDGL) is down 13.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is the company’s second-quarter earnings update landing against very elevated expectations after a strong run in the stock. This could be because investors wanted a clearer upside surprise in Rezdiffra sales, guidance, or operating leverage, and the update may not have fully cleared that bar.

Details:

Madrigal had already scheduled its second-quarter 2026 financial results release and webcast for July 30, putting earnings squarely at the center of today’s move.

Wall Street had been looking for roughly $350 million of second-quarter revenue, so expectations for continued Rezdiffra momentum were already high going into the report.

In the first quarter, Madrigal posted $311.3 million in Rezdiffra net sales and said more than 42,250 patients were on therapy as of March 31, which raised the benchmark for the next update.

The stock also entered earnings with supportive sentiment from recent analyst initiations and price-target increases, plus new patent announcements for resmetirom, increasing the chance of a sell-the-news reaction if results or outlook were merely solid rather than exceptional.

Sources:

Madrigal Pharmaceuticals, SEC, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDGL Insider Trading Activity

$MDGL insiders have traded $MDGL stock on the open market 41 times in the past 6 months. Of those trades, 0 have been purchases and 41 have been sales.

Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:

RICHARD S LEVY has made 0 purchases and 12 sales selling 5,682 shares for an estimated $2,928,716.
WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 11 sales selling 4,163 shares for an estimated $2,086,569.
MARDI DIER (EVP and CFO) has made 0 purchases and 13 sales selling 3,165 shares for an estimated $1,359,381.
DAVID SOERGEL (Chief Medical Officer) has made 0 purchases and 2 sales selling 1,886 shares for an estimated $951,980.
REBECCA TAUB sold 491 shares for an estimated $212,082
CAROLE HUNTSMAN (Chief Commercial Officer) sold 419 shares for an estimated $180,982
SHANNON T KELLEY (General Counsel) sold 360 shares for an estimated $155,498

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MDGL Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MDGL Hedge Fund Activity

We have seen 185 institutional investors add shares of $MDGL stock to their portfolio, and 170 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 417,709 shares (+1156.0%) to their portfolio in Q1 2026, for an estimated $218,658,130
PAULSON & CO. INC. removed 315,334 shares (-18.5%) from their portfolio in Q1 2026, for an estimated $165,067,888
WELLINGTON MANAGEMENT GROUP LLP added 233,556 shares (+50.6%) to their portfolio in Q1 2026, for an estimated $122,259,559
BANK OF AMERICA CORP /DE/ removed 226,498 shares (-54.4%) from their portfolio in Q1 2026, for an estimated $118,564,908
ALKEON CAPITAL MANAGEMENT LLC removed 160,000 shares (-66.7%) from their portfolio in Q1 2026, for an estimated $83,755,200
TORONTO DOMINION BANK added 130,460 shares (+inf%) to their portfolio in Q1 2026, for an estimated $68,291,896
ASSENAGON ASSET MANAGEMENT S.A. added 108,181 shares (+674.7%) to their portfolio in Q2 2026, for an estimated $58,087,787

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDGL Price Targets

Multiple analysts have issued price targets for $MDGL recently. We have seen 5 analysts offer price targets for $MDGL in the last 6 months, with a median target of $620.0.

Here are some recent targets:

Alexandria Hammond from B of A Securities set a target price of $542.0 on 06/11/2026
Srikripa Devarakonda from Truist Securities set a target price of $709.0 on 05/13/2026
Liisa Bayko from Evercore ISI Group set a target price of $649.0 on 05/07/2026
Edward Nash from Canaccord Genuity set a target price of $578.0 on 05/07/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $620.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.